Search results for " BIOMARKERS"

showing 10 items of 365 documents

“Better explanations” in multiple sclerosis diagnostic workup

2019

BackgroundThe exclusion of other diseases that can mimic multiple sclerosis (MS) is the cornerstone of current diagnostic criteria. However, data on the frequency of MS mimics in real life are incomplete.MethodsA total of 695 patients presenting with symptoms suggestive of MS in any of the 22 RIREMS centers underwent a detailed diagnostic workup, including a brain and spinal cord MRI scan, CSF and blood examinations, and a 3-year clinical and radiologic follow-up.FindingsA total of 667 patients completed the study. Alternative diagnoses were formulated in 163 (24.4%) cases, the most frequent being nonspecific neurologic symptoms in association with atypical MRI lesions of suspected vascular…

Male404241Longitudinal StudieDisease0302 clinical medicineMultiple SclerosiDiagnosisMedicine030212 general & internal medicineProspective StudiesLongitudinal StudiesProspective cohort studymedicine.diagnostic_testMagnetic Resonance Imagingclinical practiceatypical MRI lesionsMS mimicsDisease ProgressionFemaleSettore MED/26 - NeurologiaRadiologyHumanAdultmultiple sclerosis; diagnostic criteria; atypical MRI lesions; MS mimics; clinical practicemedicine.medical_specialtyMultiple Sclerosis2omarkers / metabolism Diagnosis Differential Female Follow-Up Studies Humans Longitudinal Studies Magnetic Resonance Imaging Male Multiple Sclerosis / diagnosis* Prospective StudiesArticleFollow-Up StudieDiagnosis Differential03 medical and health sciencesHumansNeuromyelitis opticabusiness.industryMultiple sclerosisAdult; Biomarkers; Diagnosis Differential; Female; Follow-Up Studies; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Prospective StudiesMagnetic resonance imagingOdds ratioBiomarkermedicine.disease101MigraineDifferentialdiagnostic criteriaNeurology (clinical)Differential diagnosisbusiness030217 neurology & neurosurgeryBiomarkersFollow-Up StudiesNeurology
researchProduct

The Gene-Environment Interactions in Respiratory Diseases (GEIRD) Project.

2009

The role of genetic and environmental factors, as well as their interaction, in the natural history of asthma, allergic rhinitis and chronic obstructive pulmonary disease (COPD) is largely unknown. This is mainly due to the lack of large-scale analytical epidemiological/genetic studies aimed at investigating these 3 respiratory conditions simultaneously. The GEIRD project is a collaborative initiative designed to collect information on biomarkers of inflammation and oxidative stress, individual and ecological exposures, diet, early-life factors, smoking habits, genetic traits and medication use in large and accurately defined series of asthma, allergic rhinitis and COPD phenotypes. It is a …

MaleAllergyDatabases FactualRespiratory Tract DiseasesEnvironmental pollutionPulmonary Disease Chronic ObstructiveSurveys and QuestionnairesEpidemiologyImmunology and AllergyLongitudinal StudiesgenesCOPDeducation.field_of_studyData CollectionGeneral MedicineNutrition SurveysNatural historyPhenotypeItalyData Interpretation StatisticalFemalecase-controlmedicine.medical_specialtyRhinitis Allergic PerennialImmunologyPopulationEnvironmentchronic obstructive pulmonary diseaserhinitisBiasmedicineHumanseducationinflammatory biomarkersAsthmaallergic rhinitisPublic Sectorbusiness.industryCase-control studyRhinitis Allergic Seasonalmedicine.diseaseAsthmagenes chronic obstructive pulmonary disease asthma rhinitis case-control environment inflammatory biomarkers dietCase-Control StudiesEpidemiologic Research DesignImmunologyHousingdietbusinessEnvironmental Pollutionasthma; allergic rhinitisInternational archives of allergy and immunology
researchProduct

Multiple hormonal and metabolic deficiency syndrome in chronic heart failure: rationale, design, and demographic characteristics of the T.O.S.CA. Reg…

2018

Recent evidence supports the concept that progression of chronic heart failure (CHF) depends upon an imbalance of catabolic forces over the anabolic drive. In this regard, multiple hormonal deficiency syndrome (MHDS) significantly has impacts upon CHF progression, and is associated with a worse clinical status and increased mortality. The T.O.S.CA. (Trattamento Ormonale nello Scompenso CArdiaco; Hormone Therapy in Heart Failure) Registry (clinicaltrial.gov = NCT02335801) tests the hypothesis that anabolic deficiencies reduce survival in a large population of mild-to-moderate CHF patients. The T.O.S.CA. Registry is a prospective multicenter observational study coordinated by “Federico II” Un…

MaleAnabolismmedicine.medical_treatment030204 cardiovascular system & hematologylaw.invention0302 clinical medicineRandomized controlled triallawClinical endpointMedicineDeficiency Disease030212 general & internal medicineProspective StudiesRegistriesProspective cohort studyTestosteroneAnabolic deficiency; Chronic heart failure; Heart failure metabolism; Multiple hormonal deficiency syndrome; Registry; Aged; Biomarkers; Chronic Disease; Deficiency Diseases; Disease Progression; Female; Heart Failure; Humans; Italy; Male; Metabolic Diseases; Middle Aged; Prospective Studies; Registries; Internal Medicine; Emergency MedicineMiddle AgedItalyEmergency MedicineDisease ProgressionFemaleHumanmedicine.medical_specialtyRegistryAnabolic deficiencyAnabolic deficiency Chronic heart failure Heart failure metabolism Multiple hormonal deficiency syndrome RegistrySocio-culturaleHeart failure metabolism03 medical and health sciencesMetabolic DiseasesInternal medicineInternal MedicineHumansAgedHeart Failurebusiness.industryMultiple hormonal deficiency syndromeSettore MED/13 - ENDOCRINOLOGIABiomarkermedicine.diseaseChronic heart failureMetabolic DiseaseProspective StudieHeart failureChronic DiseaseObservational studyHormone therapybusinessDeficiency DiseasesBiomarkersInternal and emergency medicine
researchProduct

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 tria…

2019

© 2019 Elsevier Ltd. All rights reserved.

MaleBiopsyClinical Trial Phase IIIAdministration Oral030204 cardiovascular system & hematologyChronic liver diseaseSettore MED/04Biomarkers/analysisGastroenterologychemistry.chemical_compound0302 clinical medicine/dk/atira/pure/researchoutput/pubmedpublicationtype/D013485Liver Function TestsNon-alcoholic Fatty Liver DiseaseClinical endpointMedicine030212 general & internal medicine610 Medicine & healthChenodeoxycholic Acid/administration & dosageeducation.field_of_studyLiver Function TestResearch Support Non-U.S. Gov'tFatty liverObeticholic acidNASH OBETICHOLIC ACIDGeneral Medicine/dk/atira/pure/researchoutput/pubmedpublicationtype/D052061Middle AgedMulticenter Study/dk/atira/pure/researchoutput/pubmedpublicationtype/D016448Randomized Controlled TrialAdministrationFemale/dk/atira/pure/researchoutput/pubmedpublicationtype/D016449Administration Oral; Biomarkers; Biopsy; Chenodeoxycholic Acid; Double-Blind Method; Female; Humans; Liver Function Tests; Male; Middle Aged; Non-alcoholic Fatty Liver DiseaseHumanOralmedicine.medical_specialtyPopulationPlaceboChenodeoxycholic Acid03 medical and health sciencesResearch Support N.I.H. ExtramuralDouble-Blind MethodInternal medicineJournal ArticleHumans/dk/atira/pure/researchoutput/pubmedpublicationtype/D017428educationIntention-to-treat analysisbusiness.industryBiomarkerInterim analysismedicine.diseaseNon-alcoholic Fatty Liver Disease/drug therapychemistryHuman medicine/dk/atira/pure/researchoutput/pubmedpublicationtype/D016428businessBiomarkersAdministration; Oral; Biomarkers; Biopsy; Chenodeoxycholic Acid; Double-Blind Method; Female; Humans; Liver Function Tests; Male; Middle Aged; Non-alcoholic Fatty Liver Disease
researchProduct

Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone ly…

2015

Rituximab ® provides high response rates and effective disease palliation in patients with splenic marginal zone lymphoma (SMZL). We conducted a phase II trial in patients with SMZL who were either untreated or were splenectomized but had shown disease progression within 1 year after splenectomy. Treatment consisted of six courses of Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone (R-COMP). Fifty-one patients were eligible for the analysis. The overall response rate was 84%. The 6-year progression-free survival and overall survival were 54% and 72%, respectively. Toxicity was substantial (grade ≥ 3 neutropenia: 26%; grade ≥ 3 infections: 8%).…

MaleCancer ResearchBiopsymedicine.medical_treatmentfirst lineKaplan-Meier EstimateSplenic marginal zone lymphoma; first line; rituximabPolyethylene GlycolGastroenterologyPolyethylene GlycolsrituximabBone MarrowPrednisonefirst line; rituximab; splenic marginal zone lymphomaCause of DeathAntineoplastic Combined Chemotherapy ProtocolsSplenic marginal zone lymphomaAged 80 and overHematologyMiddle AgedPrognosisCombined Modality TherapySplenic NeoplasmTreatment OutcomeItalyOncologyVincristineFemaleRituximabHumanmedicine.drugAdultmedicine.medical_specialtyVincristineLymphoma B-CellCyclophosphamidePrognosiSplenectomySplenic NeoplasmNeutropeniaImmunophenotypingfirst line; rituximab; Splenic marginal zone lymphoma; Adult; Aged; Aged 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Bone Marrow; Cause of Death; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Immunophenotyping; Italy; Kaplan-Meier Estimate; Lymphoma B-Cell; Male; Middle Aged; Polyethylene Glycols; Prednisone; Prognosis; Rituximab; Splenic Neoplasms; Treatment Outcome; Vincristine; Hematology; Oncology; Cancer ResearchInternal medicinemedicineHumansSplenic marginal zone lymphomaCyclophosphamideAgedAntineoplastic Combined Chemotherapy Protocolbusiness.industrySplenic NeoplasmsBiomarkermedicine.diseaseSurgeryDoxorubicinPrednisonebusinessBiomarkers
researchProduct

Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: Results from a multicenter study in Italy

2015

Increasing evidence indicates that common genetic variants may contribute to the heritable risk of breast cancer (BC). In this study, we investigated whether single nucleotide polymorphisms (SNPs), within the 8q24.21 multi-cancer susceptibility region and within BC-associated loci widespread in the genome, may influence the risk of BC in men, and whether they may be associated with specific clinical-pathologic characteristics of male BC (MBC). In the frame of the ongoing Italian Multicenter Study on MBC, we performed a case-control study on 386 MBC cases, including 50 BRCA1/2 mutation carriers, and 1105 healthy male controls, including 197 unaffected BRCA1/2 mutation carriers. All 1491 subj…

MaleCancer ResearchPredictive Value of Test8q24.21; BRCA1/2; Clinical-pathologic characteristics; Low-penetrance BC alleles; Male breast cancer; SNPs; BRCA1 Protein; BRCA2 Protein; Biomarkers Tumor; Breast Neoplasms Male; Case-Control Studies; Chi-Square Distribution; Gene Frequency; Genetic Predisposition to Disease; Heterozygote; Homozygote; Humans; Italy; Linear Models; Logistic Models; Male; Multivariate Analysis; Mutation; Odds Ratio; Phenotype; Predictive Value of Tests; Risk Factors; Chromosomes Human Pair 11; Chromosomes Human Pair 14; Chromosomes Human Pair 8; Chromosomes Human Pair 9; Polymorphism Single Nucleotide; Oncology; Cancer ResearchGene FrequencyRisk FactorsGenotypeOdds RatioMedicineskin and connective tissue diseasesMultivariate AnalysiSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIAGeneticsClinical-pathologic characteristicsBRCA1 ProteinClinical-pathologic characteristicHomozygoteLow-penetrance BC allelesPhenotype8q24.21OncologyItalyMale breast cancer8q24.21; BRCA1/2; Clinical-pathologic characteristics; Low-penetrance BC alleles; Male breast cancer; SNPs; Cancer Research; OncologyLinear ModelCase-Control StudieChromosomes Human Pair 9HumanChromosomes Human Pair 8SNPsHeterozygoteLogistic ModelSNPSingle-nucleotide polymorphismPolymorphism Single NucleotideBreast Neoplasms MaleBreast cancerPredictive Value of TestsBRCA1/2Biomarkers TumorSNPHumansGenetic Predisposition to DiseaseAllele frequencyBRCA2 ProteinChromosomes Human Pair 14Chi-Square Distributionbusiness.industryRisk FactorChromosomes Human Pair 11Case-control studyOdds ratiomedicine.diseaseMale breast cancerLogistic ModelsCase-Control StudiesMultivariate AnalysisMutationLinear ModelsbusinessLow-penetrance BC allele
researchProduct

Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer.

2021

Abstract Fatal neuroendocrine differentiation (NED) of castration-resistant prostate cancer is a recurrent mechanism of resistance to androgen deprivation therapies (ADT) and antiandrogen receptor pathway inhibitors (ARPI) in patients. The design of effective therapies for neuroendocrine prostate cancer (NEPC) is complicated by limited knowledge of the molecular mechanisms governing NED. The paucity of acquired genomic alterations and the deregulation of epigenetic and transcription factors suggest a potential contribution from the microenvironment. In this context, whether ADT/ARPI induces stromal cells to release NED-promoting molecules and the underlying molecular networks are unestablis…

MaleCancer ResearchStromal cellAnimals Biomarkers Tumor Cell Differentiation Cell Line Tumor Coculture Techniques Endoplasmic Reticulum Chaperone BiP Epigenesis Genetic Gene Expression Regulation Neoplastic Humans Male Mice Mice Inbred C57BL Neuroendocrine Cells Osteonectin Prostatic Neoplasms Stromal Cells Transgenes Tumor Microenvironment Down-RegulationDown-RegulationContext (language use)Settore MED/08 - Anatomia PatologicaNeuroendocrine differentiationEpigenesis GeneticProstate cancerMiceStromaDownregulation and upregulationNeuroendocrine CellsCell Line TumormedicineBiomarkers TumorTumor MicroenvironmentSettore MED/05 - Patologia ClinicaAnimalsHumansOsteonectinEpigeneticsTransgenesEndoplasmic Reticulum Chaperone BiPbusiness.industryMatricellular proteinProstatic NeoplasmsCell Differentiationmedicine.diseaseCoculture TechniquesGene Expression Regulation NeoplasticMice Inbred C57BLOncologyCancer researchStromal CellsbusinessCancer research
researchProduct

Optimal local control and tolerability of three-dimensional conformal radiation therapy in prostate cancer: A single institutional experience of dose…

2013

Aims To evaluate long-term late side effects, clinical and biochemical relapse in non-metastatic prostate cancer patients treated with dose escalation, from 74 to 78 Gy, by means of three dimensional conformal radiation therapy. Materials and Methods Clinical data of 125 patients with prostate cancer who underwent three-dimensional conformal radiation therapy were retrospectively evaluated. All patients were stratified, according to the NCCN classification, in low, intermediate and high risk, and all of them showed histologically proven adenocarcinoma stage T1–T3 with at least 2 years of follow-up. Late toxicity was analyzed using a modified Radiation Therapy Oncology Group toxicity scale. …

MaleCancer ResearchThree dimensional conformal radiation therapyUrinary BladderUrogenital SystemKaplan-Meier EstimateAdenocarcinomaDisease-Free SurvivalBiomarkers Tumor80 and overHumansLate toxicity; Local control; Prostate cancer; Radiation therapy; Three dimensional conformal radiation therapy; Adenocarcinoma; Aged; Aged 80 and over; Biomarkers Tumor; Disease-Free Survival; Gastrointestinal Tract; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Injuries; Radiotherapy Dosage; Radiotherapy Conformal; Rectum; Retrospective Studies; Urinary Bladder; Urogenital System; Medicine (all); Oncology; Cancer ResearchRadiation InjuriesAgedNeoplasm StagingRetrospective StudiesAged 80 and overProstate cancerTumorRadiotherapyConformalMedicine (all)RectumProstatic NeoplasmsRadiotherapy DosageGeneral MedicineMiddle AgedProstate-Specific AntigenRadiation therapyGastrointestinal TractItalyOncologyLocal controlRadiotherapy ConformalLate toxicityBiomarkers
researchProduct

Diastolic left ventricular function in relation to circulating metabolic biomarkers in a population study

2019

AimsWe studied the association of circulating metabolic biomarkers with asymptomatic left ventricular diastolic dysfunction, a risk-carrying condition that affects 25% of the population.Methods and resultsIn 570 randomly recruited people, we assessed in 2005–2010 and in 2009–2013 the multivariable-adjusted correlations of e’ (early left ventricular relaxation) and E/e’ (left ventricular filling pressure) measured by Doppler echocardiography with 43 serum metabolites, quantified by magnetic resonance spectroscopy. In 2009–2013, e’ cross-sectionally increased (Bonferroni corrected p ≤ 0.016) with the branched-chain amino acid valine (per one standard deviation increment, +0.274 cm/s (95% conf…

MaleCardiac & Cardiovascular SystemsMagnetic Resonance SpectroscopyTime FactorsEpidemiology030204 cardiovascular system & hematologyVentricular Function LeftVentricular Dysfunction Left0302 clinical medicineBelgiumpopulation scienceDiastole030212 general & internal medicinebranched-chain amino acidsMetabolic biomarkersVentricular functionIncidenceMiddle AgedRNA Transfer Amino Acid-SpecificPrognosismetabolomicsEchocardiography DopplerGLUTAMINECardiologyPopulation studyHEART-FAILUREFemalemedicine.symptomCardiology and Cardiovascular MedicineLife Sciences & BiomedicineAdultmedicine.medical_specialtyDiastoleAsymptomatic03 medical and health sciencesPredictive Value of TestsInternal medicineATRIALmedicineHumansAgedScience & Technologybusiness.industryBiomarkerDYSFUNCTIONBiomarker (cell)diastolic left ventricular dysfunctionAsymptomatic DiseasesCardiovascular System & CardiologyLeft ventricular diastolic dysfunctionTransfer RNA AminoacylationbusinessAmino Acids Branched-ChainBiomarkers
researchProduct

Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens

2019

Anthracyclines are the cornerstone for many oncologic treatments, but their cardiotoxicity has been recognized for several decades. Female subjects, especially before puberty and adolescence, or after menopause, seem to be more at increased risk, with the prognostic impact of this sex issue being less consistent compared to other cardiovascular risk factors. Several studies imply that sex differences could depend on the lack of the protective effect of sex hormones against the anthracycline-initiated damage in cardiac cells, or on differential mitochondria-related oxidative gene expression. This is also reflected by the results obtained with different diagnostic methods, such as cardiovascu…

MaleCardiac & Cardiovascular SystemsMagnetic Resonance Spectroscopyand protection from anthracycline cardiotoxicitymedicine.disease_causeBioinformaticsRisk FactorsAnthracycline cardiotoxicityGender differenceGender differencesAnthracyclinesGonadal Steroid Hormones1102 Cardiorespiratory Medicine and HaematologyAMERICAN SOCIETYCardioprotectionSex CharacteristicsHeartPrognosisMitochondriaMenopauseEchocardiographyReperfusion InjuryHEART-FAILUREAnthracycline cardiotoxicity; Gender differences; Pathophysiology monitoring and protection from anthracycline cardiotoxicity; Anthracyclines; Biomarkers; Cardiotonic Agents; Cardiotoxicity; Echocardiography; Female; Gonadal Steroid Hormones; Heart; Heart Failure; Humans; Magnetic Resonance Spectroscopy; Male; Mitochondria; Nuclear Medicine; Oxidative Stress; Prognosis; Reperfusion Injury; Risk Factors; Sex CharacteristicsFemaleCardiology and Cardiovascular MedicineLife Sciences & BiomedicinePOSITION PAPERCARDIAC DYSFUNCTIONCardiotonic AgentsAnthracyclineSPECKLE-TRACKINGIschemiaDRUG CARDIOTOXICITYPathophysiologymedicineHumansCHILDHOOD-CANCER SURVIVORSBREAST-CANCERPathophysiology monitoring and protection from anthracycline cardiotoxicityHeart FailureCardiotoxicityScience & Technologybusiness.industryWORKING GROUPmedicine.diseaseCardiotoxicityOxidative StressmonitoringCardiovascular System & HematologyHeart failureCardiovascular System & CardiologyRISK-FACTORSNuclear MedicinebusinessOxidative stressAnthracycline cardiotoxicity; Gender differences; Pathophysiology monitoring and protection from anthracycline cardiotoxicityBiomarkersHormone
researchProduct